Modelling population-level impact to inform target product profiles for childhood malaria vaccines

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 14 Jul 2018)

Research article
Modelling population-level impact to inform target product profiles for childhood malaria vaccines
The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot imple…
Authors: Alexandra B. Hogan, Peter Winskill, Robert Verity, Jamie T. Griffin and Azra C. Ghani
Citation: BMC Medicine 2018 16:109
Published on: 13 July 2018